Corporate news
Grifols achieves a record net profit of 470.3 million euros with growth of 36.1% in 2014 Grifols' net revenues rose by 22.4% to 3,355.4 million euros
+ info
+ info
Grifols PhocusRx Certified DIACAP Compliant The PhocusRx system can operate with a low and acceptable level of risk when installed in a Department of Defense facility that meets security requirements.
+ info
+ info
SIPPET Study on inhibitors in Hemophilia A: interim analysis confirms the original hypothesis The Study is safe to continue after Investigators' Meeting and the disclosure of interim analysis in San Francisco
+ info
+ info
Highlights
Manufacturing
We are a solid company with an international dimension.
Corporate Commitment
We contribute to improving people's health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.
New transfusion medicine solutions
Grifols is committed to helping you work efficiently to deliver blood that is safe and compatible for patients. + info
